Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
about
Cell signaling by receptor tyrosine kinasesThe PI3K pathway as drug target in human cancerEmerging molecular classifications and therapeutic implications for gastric cancerRecent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCPI3K and AKT: Unfaithful Partners in CancerTranslational implications of tumor heterogeneityThe latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC)Ten things you should know about protein kinases: IUPHAR Review 14Emerging importance of ALK in neuroblastomaSteering tumor progression through the transcriptional response to growth factors and stromaMechanisms of drug resistance in kinases.Complexities of TGF-β targeted cancer therapy.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutationsPharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyondCurrent Therapeutic Advances Targeting EGFR and EGFRvIII in GlioblastomaBlood-based analyses of cancer: circulating tumor cells and circulating tumor DNAA novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancersTargeting heat shock protein 90 for the treatment of malignant pheochromocytomaDual Inhibition of Topoisomerase II and Tyrosine Kinases by the Novel Bis-Fluoroquinolone Chalcone-Like Derivative HMNE3 in Human Pancreatic Cancer CellsRegistered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulationsSmall-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse ChemotherapeuticsAcquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3KSpherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastomaChemosensitization of cancer cells by siRNA using targeted nanogel delivery.A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway.Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.Targeting the disordered C terminus of PTP1B with an allosteric inhibitorMolecular mechanisms of acquired resistance to tyrosine kinase targeted therapyActivation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy.Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.Evolutionary dynamics of carcinogenesis and why targeted therapy does not work.Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.Differences underlying EGFR and HER2 oncogene addiction.Receptor tyrosine kinases with intracellular pseudokinase domains
P2860
Q24598357-9364C1FC-C579-497C-972E-371002CA4A20Q24632283-0A941C39-5AC6-43F9-A4D8-CFD96E27D408Q26745525-CAEE899B-8CF0-495B-B0AC-E6775A4B7B86Q26747276-F57CEE0E-DBC5-45A0-8968-E0BC862AE3F5Q26781367-7EAB1FC1-0530-42FB-957B-B1E2765544DDQ26822823-5B361A36-D046-4B72-B77B-660C6D5F1FA2Q26823305-07C50AB1-6348-4B71-9142-72903999D507Q26849417-6D6DF9B1-DB2D-4027-801D-8730FDB70A1AQ26858819-04D36270-D1D6-48DD-8A90-E2DF5FC5D3F1Q26865967-D913170D-90C7-4481-807B-1F77BF6571C5Q27692567-7FD82286-8C3C-4A5F-8CA3-BF2E40538298Q27693607-37ADF8E4-FD1A-47B8-8B74-573C35CCB276Q27851628-CA510074-19BA-4E7B-A5B9-A3D87B4A3B5DQ27851710-07AF3C2B-5BA3-48D3-B690-BA1CD7B71F22Q27852017-93394378-0033-4740-87D5-2EE257523038Q27853138-9E68B5D2-669B-40F0-938E-F78766E0F9CDQ28080730-7D93FBA3-C54D-4A64-B70A-80B42C75879BQ28087306-A812ADA0-3B0A-4352-8364-6B61979D70DDQ28239638-44F0F027-55FB-4300-A047-AFCF9AF09C3EQ28485310-D09C15EF-FCC5-46F8-A270-7F98997942E0Q28486170-42ECD575-0467-4519-A4D8-3900509CE30FQ28552765-118FFE33-7520-407F-B9F6-685126EAC049Q28603408-70F4C0AC-3218-44BC-A644-2D46C4E2AC00Q29027136-8D513298-40DF-4455-A189-0F231AE7ADBFQ29614757-D88B3A88-5706-4AE4-8EA6-1AC6C4D2A15DQ30577878-ECBC7828-2726-4FFB-90EF-9745CD862A2FQ33523195-3E2ABEC7-1ECC-4E51-A00D-DD6340C3B483Q33605906-0BC2BB23-17E3-4403-893F-123947A3C47CQ33686369-3D49C429-54B0-482D-BA8B-81D5B9A679E6Q33726782-A85FE2EC-42D6-44A8-826E-752F25EA32EDQ33774262-C0774CDD-B9B8-44FE-9C6C-0AC1537AF85CQ33828409-967A1B9B-CBEB-4C3D-9E06-272807B1AF2DQ33891230-4BA1B9CE-CD9F-4AC5-B037-C27AF39C3498Q33924077-1F07443D-BE60-41A9-9525-09997040C3BDQ33942266-F84A6D89-2728-47C7-A86B-8AEB9B5AE5DBQ34005286-19F7FEB7-5295-483B-AA56-F51D73179857Q34032640-67102B70-FF82-418A-A861-70395F1552A9Q34296575-960152BB-9072-4FAB-B399-420FBEEA6204Q34307542-26D64189-16F5-485E-A1A9-BC4DD7FE0FC5Q34358042-8CB32EB3-A643-4941-89B7-0AEFDEA0E670
P2860
Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
@en
Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
@nl
type
label
Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
@en
Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
@nl
prefLabel
Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
@en
Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
@nl
P1476
Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
@en
P2093
Jeffrey A Engelman
Jeffrey Settleman
P356
10.1016/J.GDE.2008.01.004
P577
2008-02-01T00:00:00Z